Critical assessment of influenza VLP production in Sf9 and HEK293 expression systems

BMC Biotechnology

Christine M Thompson³  Emma Petiot⁵  Alaka Mullick²  Marc G Aucoin¹  Olivier Henry³  Amine A Kamen⁴ 

[1] University of Waterloo, Waterloo, Canada

[2] National Research Council Canada, Human Health Therapeutics, Montréal, Canada

[3] Ecole Polytechnique de Montréal, Montréal, Canada

[4] Department of Bioengineering, McGill University, 817 Sherbrooke St. W. Macdonald Engineering Building, Room 387, Montréal, Canada

[5] Laboratoire Virologie et pathologies Humaine (VirPath), Lyon, EA4610, France

关键词: VLP characterization;    Process development;    Mammalian cells;    Insect cells;    Virus like particles (VLPs);    Influenza vaccines;   

Others  :  1210260
DOI  :  10.1186/s12896-015-0152-x

 received in 2015-01-05, accepted in 2015-04-22,  发布年份 2015

【 摘 要 】

Background

Each year, influenza is responsible for hundreds of thousand cases of illness and deaths worldwide. Due to the virus’ fast mutation rate, the World Health Organization (WHO) is constantly on alert to rapidly respond to emerging pandemic strains. Although anti-viral therapies exist, the most proficient way to stop the spread of disease is through vaccination. The majority of influenza vaccines on the market are produced in embryonic hen’s eggs and are composed of purified viral antigens from inactivated whole virus. This manufacturing system, however, is limited in its production capacity. Cell culture produced vaccines have been proposed for their potential to overcome the problems associated with egg-based production. Virus-like particles (VLPs) of influenza virus are promising candidate vaccines under consideration by both academic and industry researchers.

Methods

In this study, VLPs were produced in HEK293 suspension cells using the Bacmam transduction system and Sf9 cells using the baculovirus infection system. The proposed systems were assessed for their ability to produce influenza VLPs composed of Hemagglutinin (HA), Neuraminidase (NA) and Matrix Protein (M1) and compared through the lens of bioprocessing by highlighting baseline production yields and bioactivity. VLPs from both systems were characterized using available influenza quantification techniques, such as single radial immunodiffusion assay (SRID), HA assay, western blot and negative staining transmission electron microscopy (NSTEM) to quantify total particles.

Results

For the HEK293 production system, VLPs were found to be associated with the cell pellet in addition to those released in the supernatant. Sf9 cells produced 35 times more VLPs than HEK293 cells. Sf9-VLPs had higher total HA activity and were generally more homogeneous in morphology and size. However, Sf9 VLP samples contained 20 times more baculovirus than VLPs, whereas 293 VLPs were produced along with vesicles.

Conclusions

This study highlights key production hurdles that must be overcome in both expression platforms, namely the presence of contaminants and the ensuing quantification challenges, and brings up the question of what truly constitutes an influenza VLP candidate vaccine.

【 授权许可】

   
2015 Thompson et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Influenza (Seasonal) fact sheet. WHO media cent. 2014.
• [2]Cohen J. Out of Mexico? Scientists ponder swine flu’s origins. Science. 2009; 324:700-3.
• [3]Michaelis M, Doerr HW, Cinatl J. Novel swine-origin influenza A virus in humans: another pandemic knocking at the door. Med Microbiol Immunol. 2009; 198:175-83.
• [4]Gerdil C. The annual production cycle for influenza vaccine. Vaccine. 2003; 21:1776-9.
• [5]Johnson TD. Next generation of flu vaccines comming of age: cell-based technology may replace egg-based flu vaccines. Nations Health. 2010; 40:1-27.
• [6]Haynes JR. Influenza virus-like particle vaccines. Expert Rev Vaccines. 2009; 8:435-45.
• [7]Kang S-M, Song J-M, Quan F-S, Compans RW. Influenza vaccines based on virus-like particles. Virus Res. 2009; 143:140-6.
• [8]Pushko P, Tumpey TM, Bu F, Knell J, Robinson R, Smith G. Influenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice. Vaccine. 2005; 23:5751-9.
• [9]Wu C-Y, Yeh Y-C, Yang Y-C, Chou C, Liu M-T, Wu H-S et al.. Mammalian expression of virus-like particles for advanced mimicry of authentic influenza virus. PLoS One. 2010; 5: Article ID e9784
• [10]Quan F-S, Vunnava A, Compans RW, Kang S-M. Virus-like particle vaccine protects against 2009 H1N1 pandemic influenza virus in mice. PLoS One. 2010; 5: Article ID e9161
• [11]Kang S-M, Yoo D-G, Lipatov AS, Song J-M, Davis CT, Quan F-S et al.. Induction of long-term protective immune responses by influenza H5N1 virus-like particles. PLoS One. 2009; 4: Article ID e4667
• [12]Latham T, Galarza JM. Formation of Wild-Type and Chimeric Influenza Virus-Like Particles following Simultaneous Expression of Only Four Structural Proteins. Journal of Virology. 2001; 75(3):6154-65.
• [13]Pushko P, Pearce MB, Ahmad A, Tretyakova I, Smith G, Belser JA et al.. Influenza virus-like particle can accommodate multiple subtypes of hemagglutinin and protect from multiple influenza types and subtypes. Vaccine. 2011; 29:5911-8.
• [14]Smith GE, Flyer DC, Raghunandan R, Liu Y, Wei Z, Wu Y et al.. Development of influenza H7N9 virus like particle (VLP) vaccine: homologous A/Anhui/1/2013 (H7N9) protection and heterologous A/chicken/Jalisco/CPA1/2012 (H7N3) cross-protection in vaccinated mice challenged with H7N9 virus. Vaccine. 2013; 31:4305-13.
• [15]Landry N, Ward BJ, Trépanier S, Montomoli E, Dargis M, Lapini G et al.. Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenza. PLoS One. 2010; 5: Article ID e15559
• [16]López-Macías C, Ferat-Osorio E, Tenorio-Calvo A, Isibasi A, Talavera J, Arteaga-Ruiz O et al.. Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo-controlled trial of adults in Mexico. Vaccine. 2011; 29:7826-34.
• [17]D’Aoust M-A, Couture MM-J, Charland N, Trépanier S, Landry N, Ors F et al.. The production of hemagglutinin-based virus-like particles in plants: a rapid, efficient and safe response to pandemic influenza. Plant Biotechnol J. 2010; 8:607-19.
• [18]Krammer F, Schinko T, Palmberger D, Tauer C, Messner P, Grabherr R. Trichoplusia ni cells (High Five) are highly efficient for the production of influenza A virus-like particles: a comparison of two insect cell lines as production platforms for influenza vaccines. Mol Biotechnol. 2010; 45:226-34.
• [19]Tang X-C, Lu H-R, Ross TM. Baculovirus-produced influenza virus-like particles in mammalian cells protect mice from lethal influenza challenge. Viral Immunol. 2011; 24:311-9.
• [20]Bright RA, Carter DM, Daniluk S, Toapanta FR, Ahmad A, Gavrilov V et al.. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. Vaccine. 2007; 25:3871-8.
• [21]Quan F-S, Huang C, Compans RW, Kang S-M. Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus. J Virol. 2007; 81:3514-24.
• [22]Margine I, Martinez-Gil L, Chou Y, Krammer F. Residual baculovirus in insect cell-derived influenza virus-like particle preparations enhances immunogenicity. PLoS One. 2012; 7: Article ID e51559
• [23]Cox MMJ, Hollister JR. FluBlok, a next generation influenza vaccine manufactured in insect cells. Biologicals. 2009; 37:182-9.
• [24]Liu F, Wu X, Li L, Liu Z, Wang Z. Use of baculovirus expression system for generation of virus-like particles: successes and challenges. Protein Expr Purif. 2013; 90:104-16.
• [25]Chen BJ, Leser GP, Morita E, Lamb RA. Influenza virus hemagglutinin and neuraminidase, but not the matrix protein, are required for assembly and budding of plasmid-derived virus-like particles. J Virol. 2007; 81:7111-23.
• [26]Vicente T, Roldão A, Peixoto C, Carrondo MJT, Alves PM. Large-scale production and purification of VLP-based vaccines. J Invertebr Pathol. 2011; 107 Suppl:S42-8.
• [27]Côté J, Garnier A, Massie B, Kamen A, Cote J. Serum-free production of recombinant proteins and adenoviral vectors by 293SF-3 F6 cells. Biotechnol Bioeng. 1998; 59:567-75.
• [28]Petiot E, Jacob D, Lanthier S, Lohr V, Ansorge S, Kamen AA. Metabolic and kinetic analyses of influenza production in perfusion HEK293 cell culture. BMC Biotechnol. 2011; 11:1-12. BioMed Central Full Text
• [29]Alain R, Nadon F, Séguin C, Payment P, Trudel M. Rapid virus subunit visualization by direct sedimentation of samples on electron microscope grids. J Virol Methods. 1987; 16:209-16.
• [30]Le Ru A, Jacob D, Transfiguracion J, Ansorge S, Henry O, Kamen AA. Scalable production of influenza virus in HEK-293 cells for efficient vaccine manufacturing. Vaccine. 2010; 28:3661-71.
• [31]Moulès V, Terrier O, Yver M, Riteau B, Moriscot C, Ferraris O et al.. Importance of viral genomic composition in modulating glycoprotein content on the surface of influenza virus particles. Virology. 2011; 414:51-62.
• [32]Roberts PC, Lamb RA, Compans RW. The M1 and M2 proteins of influenza A virus are important determinants in filamentous particle formation. Virology. 1998; 240:127-37.
• [33]Calder LJ, Wasilewski S, Berriman JA, Rosenthal PB. Structural organization of a filamentous influenza A virus. Proc Natl Acad Sci U S A. 2010; 107:10685-90.
• [34]Elleman CJ, Barclay WS. The M1 matrix protein controls the filamentous phenotype of influenza A virus. Virology. 2004; 321:144-53.
• [35]McCown MF, Pekosz A. Distinct domains of the influenza a virus M2 protein cytoplasmic tail mediate binding to the M1 protein and facilitate infectious virus production. J Virol. 2006; 80:8178-89.
• [36]Bialas KM, Bussey KA, Stone RL, Takimoto T. Specific nucleoprotein residues affect influenza virus morphology. J Virol. 2014; 88:2227-34.
• [37]Chen BJ, Leser GP, Jackson D, Lamb RA. The influenza virus M2 protein cytoplasmic tail interacts with the M1 protein and influences virus assembly at the site of virus budding. J Virol. 2008; 82:10059-70.
• [38]Watanabe K, Shimizu T, Noda S, Tsukahara F, Maru Y, Kobayashi N. Nuclear export of the influenza virus ribonucleoprotein complex: Interaction of Hsc70 with viral proteins M1 and NS2. FEBS Open Bio. 2014; 4:683-8.
• [39]Shaw ML, Stone KL, Colangelo CM, Gulcicek EE, Palese P. Cellular proteins in influenza virus particles. PLoS Pathog. 2008; 4: Article ID e1000085
• [40]Lai JCC, Chan WWL, Kien FF, Nicholls JM, Peiris JSM, Garcia J-M. Formation of virus-like particles from human cell lines exclusively expressing influenza neuraminidase. J Gen Virol. 2010; 91(Pt 9):2022-30.
• [41]Gómez-Puertas P, Mena I, Castillo M, Vivo A, Pérez-Pastrana E, Portela A. Efficient formation of influenza virus-like particles: dependence on the expression levels of viral proteins. J Gen Virol. 1999; 80(Pt 7):1635-45.
• [42]Thompson C, Petiot E, Lennaertz A, Henry O, Kamen A. Analytical technologies for influenza virus-like particle candidate vaccines: challenges and emerging approaches. Virology Journal. 2013;10:141; 14 pages (open access).
• [43]Valle JR, Cha S, Medina F, Angel RM. Heat shock protein 90 and heat shock protein 70 are components of dengue virus receptor complex in human cells. Society. 2005; 79:4557-67.
• [44]Rossman JS, Lamb RA. Influenza virus assembly and budding. Virology. 2011; 411:229-36.
• [45]Welsch S, Müller B, Kräusslich H-G. More than one door - Budding of enveloped viruses through cellular membranes. FEBS Lett. 2007; 581:2089-97.
• [46]Haynes JR, Dokken L, Wiley J, Cawthon AG, Bigger J, Harmsen AG et al.. Influenza-pseudotyped Gag virus-like particle vaccines provide broad protection against highly pathogenic avian influenza challenge. Vaccine. 2009; 27:530-41.
• [47]Denzer K, Kleijmeer MJ, Heijnen HF, Stoorvogel W, Geuze HJ. Exosome: from internal vesicle of the multivesicular body to intercellular signaling device. J Cell Sci. 2000; 113(Pt 19):3365-74.
• [48]Hervas-Stubbs S, Rueda P, Lopez L, Leclerc C. Insect baculoviruses strongly potentiate adaptive immune responses by inducing type I IFN. J Immunol. 2007; 178:2361-9.
• [49]Molinari P, Crespo MI, Gravisaco MJ, Taboga O, Morón G. Baculovirus capsid display potentiates OVA cytotoxic and innate immune responses. PLoS One. 2011; 6: Article ID e24108